Home Newsfeeds Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38

Morgan Stanley analyst Vikram Purohit maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price target from $37 to $38.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Morgan Stanley analyst Vikram Purohit maintains Kymera Therapeutics (NASDAQ:KYMR) with a Equal-Weight and raises the price target from $37 to $38.

Citigroup Maintains Sell on Check Point Software, Lowers Price Target to $120

By Benzinga Newsdesk

July 22, 10:49 AM

Citigroup analyst Fatima Boolani maintains Check Point Software (NASDAQ:CHKP) with a Sell and lowers the price target from $122 to $120.

CHKP

From Ashes To Redemption: Bitcoin Exchange Mt. Gox Emerges From Ruins To Honor Debts

By Murtuza Merchant

November 22, 3:17 PM

Mt.

BTC

SVB Leerink Downgrades Regeneron Pharmaceuticals to Market Perform, Lowers Price Target to $630

By Benzinga Newsdesk

July 25, 6:23 AM

SVB Leerink analyst David Risinger downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Outperform to Market Perform and lowers the price target from $738 to $630.

REGN

AI Study: Synthetic Cannabinoid + Favipiravir Presents Viable Treatment Against Viral Infections, Including COVID

By Vuk Zdinjak

December 6, 11:25 AM

Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1), announced results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), sepsis, and COVID-19 through PREPAiRE, an AI

TBPMF

Morgan Stanley Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38

Related Posts

Citigroup Maintains Sell on Check Point Software, Lowers Price Target to $120

From Ashes To Redemption: Bitcoin Exchange Mt. Gox Emerges From Ruins To Honor Debts

SVB Leerink Downgrades Regeneron Pharmaceuticals to Market Perform, Lowers Price Target to $630

AI Study: Synthetic Cannabinoid + Favipiravir Presents Viable Treatment Against Viral Infections, Including COVID